These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32571915)

  • 1. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy.
    Griffiths JI; Wallet P; Pflieger LT; Stenehjem D; Liu X; Cosgrove PA; Leggett NA; McQuerry JA; Shrestha G; Rossetti M; Sunga G; Moos PJ; Adler FR; Chang JT; Sharma S; Bild AH
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):16072-16082. PubMed ID: 32571915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
    Garris CS; Luke JJ
    Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One?
    Kareva I; Luddy KA; O'Farrelly C; Gatenby RA; Brown JS
    Front Immunol; 2021; 12():668221. PubMed ID: 34531851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
    Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
    Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment.
    Azizi E; Carr AJ; Plitas G; Cornish AE; Konopacki C; Prabhakaran S; Nainys J; Wu K; Kiseliovas V; Setty M; Choi K; Fromme RM; Dao P; McKenney PT; Wasti RC; Kadaveru K; Mazutis L; Rudensky AY; Pe'er D
    Cell; 2018 Aug; 174(5):1293-1308.e36. PubMed ID: 29961579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
    Olson DJ; Luke JJ
    Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272
    [No Abstract]   [Full Text] [Related]  

  • 7. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
    Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
    J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity.
    Harrell CR; Volarevic A; Djonov VG; Jovicic N; Volarevic V
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of Single-Cell Omics in Tumor Immunology.
    Liu J; Qu S; Zhang T; Gao Y; Shi H; Song K; Chen W; Yin W
    Front Immunol; 2021; 12():697412. PubMed ID: 34177965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy.
    Gargett T; Ebert LM
    Immunol Cell Biol; 2024 Aug; 102(7):535-537. PubMed ID: 38932646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
    Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
    Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
    Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
    Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and future perspectives of T cell immunotherapy in cancer.
    de Aquino MT; Malhotra A; Mishra MK; Shanker A
    Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.
    Varn FS; Wang Y; Mullins DW; Fiering S; Cheng C
    Cancer Res; 2017 Mar; 77(6):1271-1282. PubMed ID: 28126714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
    Yan L; Tan Y; Chen G; Fan J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.
    Pérez-Romero K; Rodríguez RM; Amedei A; Barceló-Coblijn G; Lopez DH
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.